Source: Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Karin M. de Winter-de Groot, Hettie M. Janssens, Rick T. van Uum, Johanna F. Dekkers, Gitte Berkers, Annelotte Vonk, Evelien Kruisselbrink, Hugo Oppelaar, Robert Vries, Hans Clevers, Roderick H.J. Houwen, Johanna C. Escher, Sjoerd G. Elias, Hugo R. de Jonge, Yolanda B. de Rijke, Harm A.W.M. Tiddens, Cornelis K. van der Ent, Jeffrey M. Beekman. Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function. Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017

Member's Comments

No comment yet.

Related content which might interest you: Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018 Year: 2019 Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020 Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002 Sputum glucose as a marker of disease severity in adult patients with cystic fibrosis Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014 The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 Presence of mucus plugging is predictive of long term lung function in children with cystic fibrosis Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers Year: 2017 Lung function in children with cystic fibrosis liver disease Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Airway microbiota across age and disease spectrum in cystic fibrosis Source: Eur Respir J, 50 (5) 1700832; 10.1183/13993003.00832-2017 Year: 2017 Improving airway clearance in cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 169-187 Year: 2014 Genotype and progressive lung damage in adult cystic fibrosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 502s Year: 2003 Pathophysiology of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 1-13 Year: 2014 Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005 Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019 Year: 2021 Arginase in patients with cystic fibrosis airway disease Source: Annual Congress 2004 - Cystic fibrosis in the 21st century: cutting edge investigations, taxing problems Year: 2004